全球人类胰岛素市场规模、份额、趋势和成长分析报告（2026-2034）

预计人类胰岛素市场将从 2025 年的 593.9 亿美元成长到 2034 年的 1,035.3 亿美元，2026 年至 2034 年的复合年增长率为 6.37%。

随着全球糖尿病盛行率的上升，全球人类胰岛素市场也显着成长。人类胰岛素广泛用于调节糖尿病患者的血糖值，特别适用于第1型糖尿病和晚期第2型糖尿病患者。随着全球糖尿病患者人数的持续增长，对胰岛素治疗的需求也急剧增加。

多种因素正在推动人类胰岛素市场的扩张。糖尿病管理意识的提高、医疗服务可近性的改善以及製药生产技术的进步，都促进了胰岛素供应量的增加。各国政府和医疗机构也正在实施相关项目，以改善糖尿病治疗并确保患者获得必要的药物。此外，胰岛素给药系统的技术进步也提高了治疗的便利性。

随着医疗卫生系统日益重视改善糖尿病的治疗和管理，人类胰岛素市场仍前景广阔。研发工作致力于开发更有效的胰岛素製剂，并改善长期治疗效果。新兴国家医疗卫生基础设施的持续改善将进一步推动市场成长。鑑于糖尿病仍然是全球面临的一项重大健康挑战，预计对人类胰岛素治疗的需求将保持强劲。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 渗透率和成长前景分析
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场挑战
• 波特五力分析
• PESTLE分析

第四章：全球人类胰岛素市场：依产品类型划分

• 市场分析、洞察与预测
• 药品（人类胰岛素类似物及生物相似药（速效、长效、预混合料）、人类胰岛素生技药品（速效、中效、预混合料））
• 注射装置（注射笔（可重复使用注射笔、一次性注射笔）、注射针（标准注射针、安全注射针））
• 注射器
• 其他的

第五章：全球人胰岛素市场：依通路划分

• 市场分析、洞察与预测
• 零售药房
• 医院药房
• 线上零售商店
• 其他的

第六章 全球人类胰岛素市场：依疾病类型划分

• 市场分析、洞察与预测
• 1型糖尿病
• 2型糖尿病

第七章 全球人类胰岛素市场：依地区划分

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 其他亚太国家
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第八章 竞争情势

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商情况（基于现有资讯）
• 策略规划

第九章：公司简介

• 主要公司的市占率分析
• 公司简介
  • B. Braun Melsungen AG
  • Becton Dickinson And Company（BD）
  • Biocon Limited
  • Eli Lilly And Company
  • Gulf Pharmaceutical Industries PSC（Julphar）
  • Novo Nordisk A/S
  • Pfizer Inc
  • Sanofi
  • SEDICO Pharmaceutical Co
  • Wockhardt Limited
  • Ypsomed AG

The Human Insulin Market size is expected to reach USD 103.53 Billion in 2034 from USD 59.39 Billion (2025) growing at a CAGR of 6.37% during 2026-2034.

The global human insulin market has grown significantly due to the increasing prevalence of diabetes worldwide. Human insulin is widely used to regulate blood sugar levels in individuals with diabetes, particularly those with type 1 diabetes and advanced type 2 diabetes. As the number of diabetes cases continues to rise globally, the demand for insulin therapies has increased substantially.

Several factors are driving the expansion of the human insulin market. Growing awareness of diabetes management, improved healthcare access, and advancements in pharmaceutical manufacturing have contributed to higher insulin availability. Governments and healthcare organizations are also implementing programs to improve diabetes treatment and ensure patient access to essential medications. Additionally, technological improvements in insulin delivery systems are enhancing treatment convenience.

The future of the human insulin market remains promising as healthcare systems focus on better diabetes care and management. Research efforts are aimed at developing more effective insulin formulations and improving long-term treatment outcomes. Expanding healthcare infrastructure in emerging economies will further support market growth. As diabetes continues to be a major global health challenge, demand for human insulin therapies is expected to remain strong.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Product Type

• Drugs (Human Insulin Analogs and Biosimilars (Rapid Acting, Long Acting, Premixed), Human Insulin Biologics (Short Acting, Intermediate Acting, Premixed))
• Delivery Devices(Pens (Reusable Pens, Disposable Pens), Pen Needles (Standard Pen Needles, Safety Pen Needles))
• Syringes
• Others

By Distribution Channel

• Retail Pharmacies
• Hospital Pharmacies
• Online Retail Stores
• Others

By Disease Type

• Type I Diabetes
• Type II Diabetes

COMPANIES PROFILED

• B Braun Melsungen AG, Becton Dickinson and Company BD, Biocon Limited, Eli Lilly and Company, Gulf Pharmaceutical Industries PSC Julphar, Novo Nordisk AS, Pfizer Inc, Sanofi, SEDICO Pharmaceutical Co, Wockhardt Limited, Ypsomed AG
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL HUMAN INSULIN MARKET: BY PRODUCT TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Product Type
• 4.2. Drugs (Human Insulin Analogs and Biosimilars (Rapid Acting, Long Acting, Premixed), Human Insulin Biologics (Short Acting, Intermediate Acting, Premixed)) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Delivery Devices(Pens (Reusable Pens, Disposable Pens), Pen Needles (Standard Pen Needles, Safety Pen Needles)) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Syringes Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL HUMAN INSULIN MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Distribution Channel
• 5.2. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Online Retail Stores Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL HUMAN INSULIN MARKET: BY DISEASE TYPE 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Disease Type
• 6.2. Type I Diabetes Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Type II Diabetes Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL HUMAN INSULIN MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Product Type
  • 7.2.2 By Distribution Channel
  • 7.2.3 By Disease Type
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Product Type
  • 7.3.2 By Distribution Channel
  • 7.3.3 By Disease Type
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Product Type
  • 7.4.2 By Distribution Channel
  • 7.4.3 By Disease Type
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Product Type
  • 7.5.2 By Distribution Channel
  • 7.5.3 By Disease Type
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Product Type
  • 7.6.2 By Distribution Channel
  • 7.6.3 By Disease Type
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL HUMAN INSULIN INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 B. Braun Melsungen AG
  • 9.2.2 Becton Dickinson And Company (BD)
  • 9.2.3 Biocon Limited
  • 9.2.4 Eli Lilly And Company
  • 9.2.5 Gulf Pharmaceutical Industries PSC (Julphar)
  • 9.2.6 Novo Nordisk A/S
  • 9.2.7 Pfizer Inc
  • 9.2.8 Sanofi
  • 9.2.9 SEDICO Pharmaceutical Co
  • 9.2.10 Wockhardt Limited
  • 9.2.11 Ypsomed AG